15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Aprea Therapeutics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $1.20 to $5.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.07 sits 230% above the current $0.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next, consensus EPS building from about $-0.08 next quarter toward $-0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Aprea Therapeutics Inc.
As of Aug, 3 of 3 firms rate APRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
APRE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.10 – $-0.05 · 3 analysts · -76% YoY
Next period, 3 analysts expect Aprea Therapeutics Inc to earn $-0.08 a share (range $-0.10 – $-0.05), versus $-0.32 a year earlier. Full-year consensus is $-0.31, growing to $-0.29 the year after.
REVENUE · NEXT QUARTER
$184.3K
Range $0 – $737.0K · 3 analysts · -100% YoY
Revenue is expected to reach $184.3K (range $0 – $737.0K), -100.0% year-over-year. Full-year consensus is $408.5K, rising to $1.1M next year.
Top analysts covering Aprea Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APRE.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #298
Buy
$1.20+29.0% to target
Overall win rate
33%
+ Follow
#2
Robert Driscoll
Wedbush · Rank #367
Buy
$3.00+222.5% to target
Overall win rate
30%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #417
Buy
$5.00+437.6% to target
Overall win rate
33%
+ Follow
#4
Matthew Biegler
Oppenheimer
Buy
$5.00+437.6% to target
Coverage
—
+ Follow
APRE stock forecast FAQ
What is APRE's average 12-month price target?+
The 3 analysts with a live target average $3.07 for Aprea Therapeutics Inc over the next 12 months, ranging from a $5.00 high to a $1.20 low.
Is APRE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for APRE?+
The Street-high target is $5.00 (Oppenheimer), and the Street-low is $1.20 (HC Wainwright & Co.). The average of all 3 active targets is $3.07.
How many Wall Street analysts cover APRE?+
3 analysts have an active rating on Aprea Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering APRE?+
Among analysts who currently cover APRE, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #298). Their current call is Buy with a $1.20 target.
What is Aprea Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.10 – $-0.05) across 3 analysts. Full-year EPS is projected at $-0.31, rising to $-0.29 the following year.
How much revenue is Aprea Therapeutics Inc expected to report next quarter?+
Consensus revenue is $184.3K (range $0 – $737.0K). Full-year revenue is projected at $408.5K, growing to $1.1M next year.
Have analysts been upgrading or downgrading APRE lately?+
As of Aug, 3 of 3 firms rate APRE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APRE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
